22 May 2023
For the second year running, on the side-lines of the 76th World Health Assembly in Geneva, the Permanent Mission of France and the Medicines Patent Pool, were delighted to host the parallel event National & regional health security: from mRNA to a sustainable vaccine manufacturing framework, in collaboration with the World Health Organization, the World Economic Forum, CEPI and the United States National Academy of Science.
H.E. Mr. Jérôme Bonnafont, Ambassador, Permanent Representation of France to the United Nations Office in Geneva and international organisations in Switzerland, hosted the event at the French Mission in Geneva on Monday 22 May 2023.
“It will not be the infectious optimism that make a difference, but what we have committed to do! We have seen before, time pass and optimism wanes, if we don’t seize the moment, we will yet again have missed this opportunity. When we come back next year, let us celebrate how the world has changed in a year through our achievements.”
Jeremy Farrar, Chief Scientist WHO
Introductory Remarks:
The first panel unpacked key elements needed to ensure the sustainability of national regional manufacturing capacity that comes from the mRNA Technology Transfer Programme.
The second panel discussed the broader ecosystem described in the Regionalized Vaccine Manufacturing Collaborative Framework and how to equitable access to vaccines in low-middle income countries.
Opening Remarks: Victor J. Dzau, President of the US National Academy of Medicine
Closing Remarks:
Click Here To View Event Photos
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.